SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART
Werte in diesem Artikel
NEW YORK, March 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQ: IART) ("Integra") potentially breached their fiduciary duties to shareholders. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation centers around possible corporate misconduct related to Integra's manufacturing facilities.
Please contact us for more information if you have continuously owned shares of Integra Lifesciences Holdings Corp since January 2023.
[Click here for information about joining the class action]
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-lifesciences-holdings-corp---iart-302098682.html
SOURCE Pomerantz LLP
Ausgewählte Hebelprodukte auf Integra LifeSciences
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Integra LifeSciences
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Integra LifeSciences Aktie News
Integra LifeSciences Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Integra LifeSciences nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 26.07.18 | Integra LifeSciences Buy | BTIG Research | |
| 05.01.18 | Integra LifeSciences Neutral | Cantor Fitzgerald | |
| 09.11.17 | Integra LifeSciences Sector Perform | RBC Capital Markets | |
| 30.06.17 | Integra LifeSciences Overweight | Cantor Fitzgerald | |
| 02.05.17 | Integra LifeSciences Sector Perform | RBC Capital Markets |
